tradmap

STLN Starling Oncology, Inc.

$6.25 -4.21%

Data as of close

Healthcare · Services-Offices & Clinics Of Doctors Of Medicine

Starling Oncology, Inc. (STLN) is a healthcare company in the Services-Offices & Clinics Of Doctors Of Medicine industry, with a market capitalization of $637 million. Shares last traded at $6.25, 12.3% below their 52-week high. Over the past year the stock is up 36.0%. Net profit margin is -6.2%, in line with the peer median of -6.2%. Revenue grew 27.8% year over year.

Market Cap
$637M
Shares Out
101.9M
EPS (TTM)
-$0.28
P/E (TTM)*
—
P/S Ratio
1.08
P/B Ratio
—
Dividend / Share
—
Dividend Yield
—
52-Week High
$7.13
52-Week Low
$2.33
Volume (venue)
80,142
Avg Vol (3m, venue)
76,985.413

* P/E (TTM) = market cap ÷ net income over the trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year — the same basis as the peer table and the screener, so it can differ from price ÷ EPS.

Performance

1W
-0.71%
1M
-1.88%
3M
+19.50%
6M
+52.81%
YTD
+75.56%
1Y
+36.02%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
44.47
SMA (50)
$6.47
SMA (200)
$4.71
Price vs SMA50
-3.38%
Price vs SMA200
+32.56%
ATR (14)
$0.36

Full technical analysis (26 indicators, D/W/M) →

Financials

Revenue
$587M
Net Income
-$36M
Gross Margin
—
Operating Margin
-4.4%
Net Margin
-6.2%
Return on Equity
145.7%
Return on Assets
-20.4%
Current Ratio
1.36
Debt / Equity
-3.21
Revenue Growth (YoY)
+27.8%

Trailing twelve months where four consecutive quarters are reported, otherwise the latest fiscal year; revenue is the fiscal-year figure where quarterly revenue covers under half of it (typical for banks, insurers and REITs), and margins are taken on it; latest reported period ends 2026-06-30. Source: SEC EDGAR/XBRL.

Full financials — revenue, cash flow & debt over time →

Recent earnings

PeriodEPS (diluted)Reported
Q2 2026 -$0.08 2026-08-06
Q1 2026 -$0.02 2026-05-07
Q4 2025 (derived) -$0.04 2026-03-12
FY 2025 -$0.54 2026-03-12
Q3 2025 -$0.14 2025-11-13
Q2 2025 -$0.15 2025-08-13

Q4 marked "derived" = fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive, so it can differ by a cent or two from the issuer's own Q4.

Full earnings history →

Services-Offices & Clinics Of Doctors Of Medicine peers

STLN vs 11 industry peers (Services-Offices & Clinics Of Doctors Of Medicine), by market cap. Data as of close

P/S vs peers
1.08 / 0.94 med
+15% premium
Net margin vs peers
-6.2% / -6.2% med
above median
1–11 of 11
HIMSHims & Hers Health, Inc.$5.9B—2.28-5.5%-8.85%
TDOCTeladoc Health, Inc.$1.6B—0.64-6.3%+1.41%
STLNStarling Oncology, Inc.$637M—1.08-6.2%-4.21%
SBCSBC Medical Group Holdings Inc$546M11.143.1228.0%+0.66%
AIRSAirsculpt Technologies, Inc.$120M—0.80-7.8%-5.11%
LFMDLifemd, Inc.$111M551.520.670.1%+0.00%
WSTNWestin Acquisition Corp$81M91.04——+0.00%
BMGLBasel Medical Group Ltd$8M———+1.48%
CCMConcord Medical Services Holdings Ltd———-20.2%+4.94%
AUNAAuna S.A.————-0.22%
SBCWWSBC Medical Group Holdings Inc————+31.31%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.